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CORRELATES OF LONGITUDINAL USE OF COMPLEMENTARY AND
ALTERNATIVE MEDICINE AMONG PEOPLE WITH OSTEOARTHRITIS:
FINDINGS FROM THE OSTEOARTHRITIS INITIATIVE
K.L. Lapane y, S. Yang z, T. McAlindon x, C.B. Eaton k. yUniv. of
Massachusetts Med. Sch., Worcester, MA, USA; zVirginia Commonwealth
Univ., Richmond, VA, USA; x Tufts Univ., Boston, MA, USA; kMem. Hosp.
of Rhode Island, Pawtucket, RI, USA
Purpose: Although correlates of complementary and alternative
medicine (CAM) have been described using cross-sectional study
designs, data describing use patterns over time are sparse. The purpose
of this study was to describe correlates of CAM usage patterns among
persons with radiographically conﬁrmed knee osteoarthritis (OA).
Methods:We included 2,114 participants of the Osteoarthritis Initiative
with radiographic tibiofemoral knee OA in at least one knee at baseline
who had ﬁve assessments completed over 4 years. Trained interviewers
asked “During the past 6 months, did you use the following health
supplements for joint pain or arthritis?” with separate questions for
chondroitin sulfate and glucosamine (GLU/CHON). Participants also
reported use of provider based CAM (e.g. acupuncture, ayurveda,
naturopathy, biofeedback, homeopathy, Reiki, chiropractic, message)
and patient self-directed CAM therapies (e.g. biologically-based
supplements (SAME, MSM, vitamins, herbs), biologically-based diets,
biologically-based topical agents, magnet therapy, mind-body inter-
ventions (Tai Chi, Yoga, Chi Gong, or Pilates, relaxation, spiritual activ-
ities)). Correlates of treatment approach for OA considered included
sociodemographic indicators, body mass index, overall measures of
mental and physical well-being, and clinical indices of knee OA. Polyt-
omous logistic regression provided adjusted odds ratio estimates (aOR)
and 95% conﬁdence intervals (CI).
Results: Fifty-ﬁve percent reported no use of GLU/CHON at any of the
ﬁve assessments, 18.6% reported use at one or two times, 13.4% at three
or four times, and 12.8% at all assessments. Relative to non-Hispanic
Whites, Blacks had reduced odds of reports of GLU/CHON use on
multiple assessments (aOR use 1-2 times: 0.59; (95% CI: 0.41-0.86); aOR use
3-4 times: 0.38; (95% CI: 0.23-0.61); aOR use 5 times: 0.13; (95% CI: 0.06-
0.28)). Those with greater than college graduate education relative to
those with < high school education had increased odds of GLU/CHON
use on multiple assessments (aOR use 1-2 times: 1.55; (95% CI: 1.03-2.32);
aOR use 3-4 times: 1.91; (95% CI: 1.16-3.16); aOR use 5 times: 1.69; (95% CI:
1.02-2.80)). Worst pain at baseline was inversely associated with GLU/
CHON use on every assessment (WOMAC Pain aOR use 5 times: 0.69; (95%
CI: 0.53-0.89). Increased quality of life at baseline was inversely corre-
lated with GLU/CHON use at every assessment ((KOOS Quality of Life
aORuse 5 times: 0.81; (95% CI: 0.65-1.00). Increased K-L grade tended to
correlate with increased GLU/CHON use reports on multiple assess-
ments. Patients reporting other self-directed CAM practices at baseline
were more likely to report GLU/CHON use on multiple assessments
((aOR use 1-2 times:1.94; (95% CI: 1.46-2.57); aOR use 3-4 times: 2.36; (95%
CI:1.71-3.26); aOR use 5 times: 3.15; (95% CI: 2.26-4.37)). Relative to
Whites, Blacks were more likely to report self-directed CAM use on
multiple assessments and less likely to report provider-based CAM use.
Women were more likely to report self-directed CAM use on multiple
assessments. Patients who reported multiple CAM approaches at
baseline (e.g. patient-based CAM, provider-based CAM, GLU/CHON)
were more likely to report use of such approaches on multiple
assessments.
Conclusions: CAM therapies are commonly used to treat joint and
arthritis pain among persons with knee OA, but reports of use over
time is limited. The extent to which low use of CAM on multiple
assessments is owing to lack of effectiveness or other factors remains
unknown.
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EFFECT OF A TOPICAL CREAM CONTAINING MUCOPOLYSACCHARIDES
ON KNEE FUNCTION AND PAIN INTENSITY OF PATIENTS WITH
OSTEOARTHRITIS
I. Möller y, M. Cid z, C. Chetrit z, D. Martinez-Puig z. y Inst. Poal de
Reumatologia, Barcelona, Spain; zBioiberica S.A., Palafolls, Spain
Purpose: To examine the effect of a topical cream consisting of muco-
polysaccharides and hyaluronic acid (Hialsorb) on knee pain and joint
function in patients diagnosed with osteoarthritis (OA) of one or both
knees.Methods: Sixty patients diagnosed with knee OA were echographically
evaluated and randomly assigned to one of 2 treatment groups: (1)
Physical therapy (n¼30; age 46.61.17) and (2) Physical therapy plus
Hialsorb cream (n¼30; age 46.00.88). Physical therapy included 20
massage sessions uniformly distributed during 60 days. Topical cream
was applied twice per day during a period of 60 days on patients of
group 2. Patients were tested at baseline (day 0) and at the end of the
intervention (day 60). Outcomes included pain visual analogue scale
(VAS) and Lequesne index.
Results: Echographic evaluation at baseline revealed that 83% of the
patients had synovial effusion, 57% tendinopathy and 30% Baker cyst.
Physical therapy alone decreased Lequesne index (37%) and knee pain
(34%) at day 60 compared to baseline (p<0.01). The combination of
physical therapy with Hialsorb cream reduced Lequesne index (70%)and
knee pain score (62%) to a greater extent than physical therapy alone
(p<0.01). At day 60 differences between groups were signiﬁcant for
knee pain (4.10.13 cm for physical therapy vs. 2.50.23 cm for the
combination; P<0.01) and for Lequesne index (5.10.23 vs. 2.90.28 for
physical therapy and the combination respectively; P<0.01). A time*-
group interaction was signiﬁcant for VAS (P<0.001) and for Lequesne
index (P<0.001).
Conclusions: Topical application of Hialsorb is effective in improving
the function and relieving the pain from OA of the knee.561
ENHANCED BIOMECHANICAL CLOSED KINETIC CHAIN THERAPY
INTERVENTION IN THE REHABILITATION OF PATIENTS AFTER
TOTAL HIP ARTHROPLASTY
Y. Kosashvili y, L. Yaari y, G. Segal z, Y. Baruch y, S. Velkes y, A. Mor z, R.
Debi x, B. Bernfeld k, A. Elbaz z. yRabin Med. Ctr., Petah Tikva, Israel;
zApos Med. and Sports Technologies, Herzliya, Israel; xBarzilay Med. Ctr.,
Ashkelon, Israel; kCarmel Med. Ctr., Haifa, Israel
Purpose: Some patients after total Hip Arthroplasty (THA) may suffer
from a limp and periarticular discomfort due to muscle weakness.
Physiotherapy is important in restoring muscle strength. Evidence-
based guidelines on rehabilitation after THA are scarce. We examined
the immediate and longer term effect of closed kinetic chain exercises
(AposTherapy) causing controlled perturbations over gait parameters
after THA.
Methods: Thirty three patients were prospectively followed during the
study. Gait parameters were measured at initial evaluation, after 15
minutes of therapy and after 3 months of treatment. SF-36 andWOMAC
scores were ﬁlled by patients before treatment and after 3 months of
treatment.
Results: Gait velocity, single limb support (SLS) and step length of the
operated leg signiﬁcantly improved after a single 15 minute treatment
(72.9 cm/s vs. 87.6 cm/s, 33.3% vs. 35.2 % of gait cycle and 45.8 cm vs.
50.2 cm, respectively, p<0.001) and furthermore after 3 months of
treatment (72.9 cm/s vs. 108.5 cm/s, 33.3% vs. 38.2 % of gait cycle and
45.8 cm vs. 56.7 cm, respectively, p<0.001). Forty three percent of
patients had a normal gait velocity after 3 months of treatment; SF-36
and WOMAC scores signiﬁcantly improved after 3 months of treatment
(p<0.008).
Conclusions: Using a closed kinetic chain exercise implemented by
a foot-worn platform is useful for patients post THA. Improvement in
gait, limb functionality, stiffness and pain may be seen after a single
session and may be more noticeable after 3 months of treatment.562
SELECTIVE RAR GAMMA ANTAGONIST LY2813631 PROTECTS AGAINST
RETINOID INDUCED CARTILAGE DEGRADATION IN PRECLINICAL
MODELS OF ARTHRITIS
B.H. Norman, A. Geiser, M. Chambers, T. Moore, S. Chandrasekhar, T.
Page, T. Bleisch, P. Mitchell. Eli Lilly and Company, Indianapolis, IN
Purpose: It has been shown that the natural ligand for the Retinoic Acid
Receptors (RARs), All Trans Retinoic Acid (ATRA), is deleterious to
articular cartilage health and is associated with the breakdown of
cartilage in osteoarthritis. Additionally, it has been shown that retinoid
levels are increased in the synovial ﬂuid of OA patients. Both natural and
synthetic retinoids (RAR agonists) are catabolic to cartilage, block early
chondrogenesis and promote chondrocyte hypertrophy via RAR
signaling through three RAR subtypes (RAR alpha, beta and gamma). It
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retinoid-mediated cartilage destruction and a RAR pan antagonist was
previously shown to improve clinical scores in the collagen-induced
arthritis (CIA) model, albeit with unacceptable adverse effects on testes.
We have postulated that the primary beneﬁcial joint effects of RAR
antagonists are associated with RARgamma, while the adverse effects
on testes are associated with RARalpha. Thus, we have identiﬁed
a highly selective RARgamma antagonist (LY2813631) to test this
hypothesis.
Methods: The RAR antagonist LY2813631 demonstrated in vitro selec-
tive afﬁnity for RARgamma in a SPA-based binding assay using full
length RAR alpha, beta and gamma protein and the synthetic pan
agonist 3H-TTNPB. Functional antagonism and selectivity was demon-
strated using a GAL4- RAR alpha, beta and gamma and Gal4 response
element/Luciferase constructs, co-transfected into HEK 293 cells.
Functional activity in chondrocytes was demonstrated using agonist
TTNPB and primary bovine chondrocytes, looking at the ability of
LY2813631 to regulate OA-relevant genes, such as MMP13, ADAMTS-5
and Type 2 Collagen. In vivo studies utilized Lewis rats to show reversal
of RAR gamma agonist induced changes in OA relevant genes in the
articular cartilage and reduction in OA-related neoepitopes in the
synovial ﬂuid. The collagen induced arthritis (CIA) model was used to
determine joint efﬁcacy in rats.
Results: In vitro, LY2813631 binds RARgamma (Ki ¼ 0.74 nM) with
signiﬁcantly higher afﬁnity than RARalpha (Ki ¼ 400 nM) and RAR beta
(Ki ¼ 25 nM) and shows selective functional antagonism at RAR gamma
(Kb ¼ 42 nM) in HEK 293 cells, compared to RARalpha (Kb ¼ 2010 nM)
and RAR beta (Kb ¼ 359 nM). Additionally, LY2813631 normalized RAR
agonist-induced increases in the catabolic enzyme ADAMTS-5 in
primary bovine chondrocytes. In vivo, a selective RARgamma agonist
was shown to increase mRNA levels of ADAMTS-5 and decrease mRNA
levels of type 2 collagen in the articular cartilage of rats after 3 days of
oral dosing. The animals also showed a 5-fold increase in the type 2
collagen neoepitopes 9A4 and CTX-II in synovial ﬂuid. These effects
could be blocked by co-dosing RARgamma antagonist LY2813631,
demonstrating speciﬁc RARgamma-mediated target engagement in the
joint space. LY2813631 also improved ankle and knee histopathology
scores in the rat CIA model at doses that did not cause testicular
degeneration.
Conclusions: Our ﬁndings support a role for endogenous retinoids in
the destruction of articular cartilage in OA and suggest that these effects
are primarily mediated through RARgamma signaling. We have also
shown that the beneﬁcial effects of RARgamma antagonist LY2813631
can be demonstratedwithout concomitant adverse effects on the testes,
supporting RARgamma as a potentially safe target for disease modiﬁ-
cation in arthritic diseases.
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IDENTIFICATION OF ENHANCERS OF BMP SIGNALING PATHWAY
WITH CARTILAGE ANABOLIC PROPERTIES
M. Daans y, G. De Wilde y, H. Klaassens z, M. Eijken y, K. Braem x, A. Garcia
de Vinuesa k, R. Lories x, P. Ten Dijke k, A. Marchand z, T.
Trimborn y. yArcarios NV, Diepenbeek, Belgium; zCD3-Cistim, Leuven,
Belgium; xCatholic Univ. Leuven, Leuven, Belgium; kUniv. Leiden, Leiden,
The Netherlands
Purpose: Modulation of the BMP pathway remains an attractive target
for development of novel anabolic treatments for osteoarthritis. We are
aiming to identify chondro-speciﬁc small molecule enhancers of the
BMP pathway. The ideal compound promotes the anabolic potential of
the chondrocytes without pushing the cells into hypertrophy and does
not induce/enhance TGFb-driven tumor formation/metastasis. We used
a “chemical biology approach”whereby 25K compounds were screened
in a BMP reporter cell-line for their enhancing activity. Next, we applied
“phenotypic ﬁlter assays” to identify compounds with the desired
proﬁle. Like this, we take full advantage of the diversity available in the
chemical library and maximize our chances to come up with innovative
modulators of BMP pathway possessing tissue selective capacities and
no/minor side effects.
Methods: 25K compounds were screened in a BMP reporter cell line for
their BMP enhancing potential at 10mM (%PAC > 68%). Cytotoxic and
general enhancers have been removed (NFkB counterscreen).
Commercially available hit-analogues were ordered, evaluated in the
BMP reporter (hit explosion) and in primary human adult articular
chondrocytes in alginate bead culture system at 10mM to selectpromising series. The effect on aggrecan production was evaluated in
the interterritorial matrix of the beads using a commercially available
ELISA and gene expression proﬁle was studied on the cell pellet using
qRT-PCR (COL2, ACAN, SOX9, MIA, COL1, BGLAP). Medicinal chemistry
efforts produced > 300 derivatives of promising series. Potency was
evaluated as previously described and used to identify SAR of the series.
In addition, tissue selectivity (osteogenic differentiation assay, TGFb-
driven tumor formation in lung ﬁbroblasts and breast cancer cell
invasion model) and pathway speciﬁcity (TGFb reporter/NFkB (TNF)
reporter) were performed to eliminate series/compounds showing
unselective/aspeciﬁc side effects.
Results: From the 25K compounds, hits belonging to 12 chemical series
were identiﬁed showing > 68% enhancement in the BMP reporter,
showing no toxicity in hepG2 cells nor general transcriptional activa-
tion. Hit explosion conﬁrmed the initial results and provided basic SAR.
Using primary human chondrocytes the most promising series showed
a concentration-dependent increase of aggrecan production; COL2,
ACAN and MIA upregulation; no effect on hypertrophy-associated
genes. The selected series are pathway speciﬁc (no TGFb enhancement -
no TNF enhancement), tissue selective (no enhancement of osteogenic
differentiation) and enhance/induce no TGFb-driven tumor formation/
metastasis. Following hit to lead optimization, SAR has been reﬁned and
potency (EC50) already improved to sub-micromolar range.
Conclusions: Using this chemical biological approach we identiﬁed
novel series showing pro-anabolic properties in the articular cartilage,
tissue selectivity and pathway speciﬁcity, with no to minimal side
effects (toxicity, TGFb-driven tumor formation/metastasis) and a clear
structure activity relationship. Further in vitro and in vivo activity
testing is ongoing and results are expected soon.564
ADJUDICATION PROCESS FOR JOINT EVENTS OF INTEREST IN
FULRANUMAB CLINICAL TRIAL PROGRAM
R. Moskowitz y, K. Brandt z, M. Lequesne x, M.A. Mont k, B. Kneeland {, P.
Sanga #, A. Mayorga #, K.M. Kelly #, D. Upmalis #, J. Thipphawong #, P.
Pierce #. yDiv. of Rheumatology, Univ. Hosp. Case Med. Ctr., Cleveland,
OH, USA; zDept. of Med., Univ. of Kansas Med. Ctr., Fairway, KS, USA;
xRheumatology Dept., Hosp. Leopold Bellan, Paris, France; k The Rubin
Inst. for Advanced Orthopedics and The Ctr. for Joint Preservation and
Replacement, Sinai Hosp. of Baltimore, Baltimore, MD, USA; {Dept. of
Radiology, Pennsylvania Hosp., Philadelphia, PA, USA; # Janssen Res. &
Dev., LLC, Titusville, NJ, USA
Purpose: Fulranumab, a novel human anti-nerve growth factor
monoclonal antibody, has demonstrated efﬁcacy compared with
placebo in improving chronic pain and functional impairment in
patients with knee or hip osteoarthritis (OA). Unexpected joint
replacements and adverse events suspicious of rapidly progressive OA
(RPOA) or osteonecrosis (ON), however, led the US Food and Drug
Administration to place all ongoing fulranumab studies on clinical hold
in December 2010. Accordingly, an independent Adjudication
Committee (AC) was established by the sponsor to develop deﬁnitions
of ON and RPOA consistent with the literature and the adjudicators’
experience; review suspicious cases and render diagnoses based on
blinded X-ray and clinical data; and attribute causality based on clinical
data.
Methods: Adjudicators were selected for their expertise in ON, RPOA,
rheumatology, orthopedic surgery, or radiology. For each case of joint
replacement and adverse event possibly related to joint destruction, the
AC agreed bymajority vote on one of 5 predeﬁned diagnoses: ON, RPOA,
RPOA with a component of, or advancing to, ON (RPOA+ON), normal
progression of OA (NPOA), or insufﬁcient information (II). During case
review, adjudicators were blinded to the patient's assignment to study
drug and to previous radiologic diagnoses. Adjudicators assessed the
case diagnoses based on structural evidence from available joint
radiographs and clinical data. Case attributions were based on clinical
evidence with the attributes of "deﬁnitely related", "probably related",
"possibly related", and "not related”.
Results: The adjudicators adopted the following deﬁnitions:
ON
Radiologic evidence:
 X-Ray: diagnosis of ON (based on: Cystic and sclerotic changes;
collapse of the femoral head, femoral condyle, or tibial plateau;
